These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 18226002

  • 1. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients.
    Rodby RA.
    Semin Dial; 2008; 21(2):145-9. PubMed ID: 18226002
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications.
    Houck CM, Pristave RJ, Kannensohn KJ.
    Semin Dial; 2008; 21(2):166-70. PubMed ID: 18226003
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis: a sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment?
    Willicombe M, Cunningham J.
    Semin Dial; 2008; 21(2):140-1. PubMed ID: 18226007
    [Abstract] [Full Text] [Related]

  • 5. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 6. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
    Todd DJ, Kagan A, Chibnik LB, Kay J.
    Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis: a nephrologist's perspective.
    Saab G, Cheng S.
    Hemodial Int; 2007 Oct; 11 Suppl 3():S2-6. PubMed ID: 17897106
    [Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A, Fogel M, Cowper SE.
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
    [Abstract] [Full Text] [Related]

  • 9. Tissue deposition of gadolinium and development of NSF: a convergence of factors.
    Perazella MA.
    Semin Dial; 2008 Mar; 21(2):150-4. PubMed ID: 18226004
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
    Penfield JG, Reilly RF.
    Semin Dial; 2008 Mar; 21(2):129-34. PubMed ID: 18225999
    [Abstract] [Full Text] [Related]

  • 12. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA.
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.
    Perazella MA, Reilly RF.
    Semin Dial; 2008 Feb; 21(2):171-3. PubMed ID: 18226005
    [Abstract] [Full Text] [Related]

  • 14. [Nephrogenic systemic fibrosis].
    Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A.
    G Ital Nefrol; 2008 Feb; 25(1):14-20. PubMed ID: 18264914
    [Abstract] [Full Text] [Related]

  • 15. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 16. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM.
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [Abstract] [Full Text] [Related]

  • 17. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E, Semelka RC, Cakit C.
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [Abstract] [Full Text] [Related]

  • 18. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Jul; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS, Sheller A.
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [Abstract] [Full Text] [Related]

  • 20. Can the risk of gadolinium be extrapolated to lanthanum?
    De Broe ME.
    Semin Dial; 2008 Sep; 21(2):142-4. PubMed ID: 18248522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.